Items in cart [0] Questions? Call 888-624-8373

PAPERBACK list:$37.00 Web:$33.30 add to cart PDF BOOK your price: $28.50 add to cart Rights & Permissions Free Resources PDF EXECUTIVE SUMMARY Display this book on your site! Related Titles Preventing HIV Infection among Injecting Drug Users in High Risk Countries: An Assessment of the Evidence Improving the Quality of Health Care for Mental and Substance-Use Conditions: Quality Chasm Series Other Related Titles The Development of Medications for the Treatment of Opiate and Cocaine Addictions: Issues for the Government and Private Sector (1995) Institute of Medicine (IOM) Web Search Builder Use this book's key terms to search within this book, across our collection, or across the Web. Skim This Chapter Skim this chapter and use this chapter's key terms to search within this book. Reference Finder Paste in your own text to find books that relate to your topic. Page 201   E-mail  Facebook  Digg  Stumble  Twitter More Page 201 Front Matter (R1-R20) Executive Summary (1-25) 1 Introduction (26-42) 2 Overview of the State of Scientific Knowledge Concerning Drug Addiction (43-73) 3 Assessment of the Medications Development Division (74-94) 4 Treatment Setting and Effectiveness (95-119) 5 Treatment Financing and Trends in Health Insurance (120-133) 6 Training and Education (134-153) 7 Federal Laws and Regulations (154-172) 8 State Laws and Regulations (173-186) 9 Market Obstacles and Creating Incentives (187-200) Appendix A: Acknowledgments (201-206) Appendix B: Organization and Mission Statements of NIDA's Medications Development Division and Its Branches (207-210) Appendix C: Diagnostic Criteria for Psychoactive Substance Dependence (211-214) Appendix D: Survey of Pharmaceutical Companies (215-226) Appendix E: Model Federal Programs in Pharmaceutical R&D (227-237) Appendix F: Workshop Agenda and Participants (238-241) Appendix G: Health Care Reform Legislation (242-247) Appendix H: Acronyms (248-250)

Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 201
Appendix A Acknowledgments The committee would like to thank the following persons who shared their expertise. John Abbott National Institute on Drug Abuse John Ambre American Medical Association Robert Angarola Hyman, Phelps and McNamara Douglas Anglin University of California Bruce Artim National Institutes of Health Dennis Baker Texas Department of Health John F. Beary Pharmaceutical Research and Manufacturers of America 201 Martin Becker, Esq. New York, NY Walter Bell National Institute of Neurological Disorders and Stroke Leslie Benet University of California Shawn Bentley Senate Judiciary Committee Alex Bradford BioDevelopment Corporation Peter Bridge National Institute on Drug Abuse Bruce Burlington Food and Drug Administration

OCR for page 202
202 DEVELOPMENT OF MEDICATIONS William Butynski National Association of State Alcohol and Drug Abuse Directors Robert Callahan American Society of Addiction Medicine, Inc. Neal Castagnoli Virginia State University John Coleman Drug Enforcement Administration Shirley Coletti McCormick Research Center Joseph Collins Department of Veterans Affairs Tim Condon National Institute on Drug Abuse Gary Coody Texas Department of Health James Cooper National Institute on Drug Abuse Addle Corradi New York State Office of Alcoholism and Substance Abuse Services Paul Coulis National Institute on Drug Abuse Lee Cummings National Institute on Drug Abuse Albert Derivan Wyeth-Ayerst Research George DeVaux BioDevelopment Corporation Kay Dickersin University of Maryland School of Medicine Carl W. Dieffenbach National Institute of Allergy and Infectious Diseases Herman Diesenhaus Substance Abuse and Mental Health Services Administration Christopher Doherty Fox, Bennett and Turner Jack Durell Treatment Research Institute Robert Eaton Pharmaceutical Manufacturers Association Barbara Espey Massachusetts Department of Public Health Susan Everingham RAND Rachel Feldman Lewin-VHI, Inc. Marian Fischman Columbia University

OCR for page 203
APPENDIX A Michael Friedman National Cancer Institute Judy Galloway Substance Abuse and Mental Health Services Administration Fred Garcia Office of National Drug Control Policy Ronald Garity Medco Behavioral Care Ann Geller American Society of Addiction Medicine Dee Gillespie DuPont Pharmaceutical Thomas Gitchel Drug Enforcement Administration Richard Golden Department of Alcohol and Drug Programs, State of California Avram Goldstein Stanford University Frederick K. Goodwin National Institute of Mental Health Eric Goplerud Substance Abuse and Mental Health Services Administration 203 John Gregrich Office of National Drug Control Policy Steve Grossman Hill and Knowlton Charles Grudzinskas National Institute on Drug Abuse Gene Haislip Drug Enforcement Administration Louis Harris Medical College of Virginia Christine Hartel National Institute on Drug Abuse Henrick Harwood Lewin-VHI, Inc. Richard Hawks National Institute on Drug Abuse Rebecca Henderson Massachusetts Institute of Technology Carol Hubner National Institute on Drug Abuse James Isbister Pharmavene, Inc. David Joranson University of Wisconsin Medical School

OCR for page 204
204 DEVELOPMENT OF MEDICATIONS Ruth Kahn Health Resources and Services Administration Janice F. Kauffman Substance Abuse Treatment Services Tom Kellenberger Medco Containment Services Richard Kilburg Johns Hopkins University Richard Kitz Massachusetts General Hospital Delbert Konnor American Managed Care Pharmacy Association Thomas Kosten Yale University Harvey Kupferberg National Institute of Neurological Disorders and Stroke Laurie Kurtzman New York State Office of Alcoholism and Drug Abuse Services Irwin Lerner Hoffmann-La Roche Robert Levy Wyeth-Ayerst Research David Lewis Brown University Robert Lubran Substance Abuse and Mental Health Services Administration Karen Marquis Wyeth-Ayerst David W. Martin, Jr. Du Pont Merck Pharmaceutical Company David McCann National Institute on Drug Abuse Mary Elizabeth McCaul Johns Hopkins University Hospital Howard McClain Drug Enforcement Administration Catherine McCormack Generic Pharmaceutical Industry Association Thomas McLellan Penn-VA Center for Studies of Addiction Daniel Melnick Substance Abuse and Mental Health Services Administration Richard Merrill University of Virginia School of Law Harry Meyer American Cyanamid Company

OCR for page 205
APPENDIX A Corrine Moody Food and Drug Administration Ed Morgan Substance Abuse and Mental Health Services Administration Dave Neuenschwander Mallinckrodt Chemical, Inc. Stuart Nightingale Food and Drug Administration Stanley Novick National Alliance of Methadone Advocates John A. Gates Vanderbilt University Mark Parrino American Methadone Treatment Association Nancy Payte Drug Dependence Associates Thomas Payte Drug Dependence Associates Dana Peale Cure is Not Worse Chris Putala Senate Judiciary Committee Scott Reines Merck Research Laboratories Nicholas P. Reuter Food and Drug Administration 205 Peter Riddell RAND Barbara Roberts Office of National Drug Control Policy Sheri L. Samotin The Wilkerson Group, Inc. Charles Sanders Glaxo Inc. Frank Sapienza Drug Enforcement Administration Alan Sartorelli Yale University School of Medicine Clifford Scharke National Institutes of Health Saul Schepartz National Cancer Institute David Schieser California Research Advisory Panel Sam Schildhaus Office of National Drug Control Policy Ian Shaffer Value Behavioral Health Dale Shoemaker National Cancer Institute

OCR for page 206
206 DEVELOPMENT OF MEDICATIONS Robert Sisko International Coalition for Addict Self Help Eve Slater Merck Research Laboratory Michael Smith Lincoln Hospital, New York Marvin Snyder National Institute on Drug Abuse Solomon Snyder Johns Hopkins University Steve Tabscot Texas Methadone Provider Group Robert Temple Food and Drug Administration John Thomas BioDevelopment Corporation Richard Thoreson Substance Abuse and Mental Health Services Administration Alan Trachtenberg National Institute on Drug Abuse Frank Vocci National Institute on Drug Abuse Jeane Van Lear Biotechnology Industry Organization William Vodra Arnold and Porter Ellen Weber Legal Action Center Bonnie Wilford George Washington University Curtis Wright Food and Drug Administration Paul Wohlford Substance Abuse and Mental Health Services Administration Thomas Wyatt National Association of State Controlled Substance Authorities Michael Young Proctor & Gamble

Representative terms from entire chapter:

substance abuse